KR102594083B1 - Mic 항체 및 결합제 및 이의 사용 방법 - Google Patents

Mic 항체 및 결합제 및 이의 사용 방법 Download PDF

Info

Publication number
KR102594083B1
KR102594083B1 KR1020227046132A KR20227046132A KR102594083B1 KR 102594083 B1 KR102594083 B1 KR 102594083B1 KR 1020227046132 A KR1020227046132 A KR 1020227046132A KR 20227046132 A KR20227046132 A KR 20227046132A KR 102594083 B1 KR102594083 B1 KR 102594083B1
Authority
KR
South Korea
Prior art keywords
cancer
ser
delete delete
thr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227046132A
Other languages
English (en)
Korean (ko)
Other versions
KR20230012072A (ko
Inventor
제니퍼 동란 우
Original Assignee
칸큐어 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칸큐어 엘엘씨 filed Critical 칸큐어 엘엘씨
Priority to KR1020237036123A priority Critical patent/KR20230152783A/ko
Publication of KR20230012072A publication Critical patent/KR20230012072A/ko
Application granted granted Critical
Publication of KR102594083B1 publication Critical patent/KR102594083B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
KR1020227046132A 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법 Active KR102594083B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237036123A KR20230152783A (ko) 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063049012P 2020-07-07 2020-07-07
US63/049,012 2020-07-07
PCT/US2021/040445 WO2022010847A1 (en) 2020-07-07 2021-07-06 Mic antibodies and binding agents and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237036123A Division KR20230152783A (ko) 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20230012072A KR20230012072A (ko) 2023-01-25
KR102594083B1 true KR102594083B1 (ko) 2023-10-25

Family

ID=77127088

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227046132A Active KR102594083B1 (ko) 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법
KR1020237036123A Pending KR20230152783A (ko) 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237036123A Pending KR20230152783A (ko) 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법

Country Status (9)

Country Link
US (2) US12139539B2 (enExample)
EP (1) EP4178678A1 (enExample)
JP (2) JP7854948B2 (enExample)
KR (2) KR102594083B1 (enExample)
CN (1) CN116249716A (enExample)
AU (1) AU2021305084A1 (enExample)
CA (1) CA3184940A1 (enExample)
TW (1) TWI925854B (enExample)
WO (1) WO2022010847A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4423140A4 (en) * 2021-10-27 2025-10-01 Samyang Biopharm Usa Inc ANTI-MIC ANTIBODIES WITH VARIANT FC DOMAINS
WO2023225626A2 (en) * 2022-05-20 2023-11-23 Adanate, Inc. Multi-targeting lilrb antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120315287A1 (en) 2011-05-31 2012-12-13 University Of Washington Through Its Center For Commercialization Mic-binding antibodies and methods of use thereof
US20160368991A1 (en) * 2013-07-05 2016-12-22 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
WO2020086776A1 (en) * 2018-10-23 2020-04-30 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
EP1082411A2 (en) 1998-06-02 2001-03-14 Dendreon Corporation Method for preparation and in vivo administration of antigen presenting cell composition
US6512162B2 (en) 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
US20030167531A1 (en) 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2388432A1 (en) 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
AU1811801A (en) 1999-12-03 2001-06-12 Dendreon Corporation Cryopreservation of antigen-loaded dendritic cells and their precursors in serum-free media
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US7060279B2 (en) 2000-03-30 2006-06-13 Dendreon Corporation Compositions and methods for dendritic cell-based immunotherapy
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US20080196111A1 (en) 2005-03-18 2008-08-14 Innate Pharma S.A. Expression Vectors and Methods for Obtaining Nk Cell Specific Expression
US20100111973A1 (en) 2006-09-22 2010-05-06 Glenn Dranoff Methods for treating mica-related disorders
ES2550384T3 (es) 2008-12-18 2015-11-06 Dana-Farber Cancer Institute, Inc. NKG2D-Fc para la inmunoterapia
WO2012091756A1 (en) 2010-12-30 2012-07-05 Avidbiotics Corp. Non-natural mic proteins
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
DK2760471T3 (en) 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
JP6405242B2 (ja) 2012-02-07 2018-10-17 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｍｉｃａ結合剤
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
WO2015179627A1 (en) 2014-05-21 2015-11-26 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
BR112017008042A2 (pt) 2014-10-20 2017-12-26 Juno Therapeutics Inc métodos e composições para dosagem em terapia de célula adotiva
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
EP3288569A4 (en) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
ES2958720T3 (es) 2015-06-10 2024-02-13 Immunitybio Inc Células NK-92 modificadas para tratar el cáncer
MX2018006785A (es) 2015-12-04 2018-11-09 Dana Farber Cancer Inst Inc Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer.
AU2016366677A1 (en) 2015-12-09 2018-07-26 Nantcell, Inc. Compositions and methods for treatment of HER2 positive metastatic breast cancer
WO2018073648A1 (en) 2016-10-19 2018-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
AU2018231193B2 (en) 2017-03-08 2021-07-22 Immunitybio, Inc. Modified NK-92 haNK003 cells for the clinic
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
WO2019004550A1 (ko) 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
US12036241B2 (en) 2017-07-19 2024-07-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
KR20200035999A (ko) 2017-08-04 2020-04-06 난트케이웨스트, 인크. Nk-92 세포를 이용한 백혈병의 치료 및 억제
EP4516896A3 (en) 2017-08-09 2025-05-14 Juno Therapeutics, Inc. Methods and compositions for preparing genetically engineered cells
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
KR102832008B1 (ko) 2018-07-31 2025-07-10 컬리난 미카 코퍼레이션 Mica/b 유출을 차단하는 항-mica/b 항체 및 사용 방법
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
EP4017876A4 (en) 2019-08-23 2023-09-06 Northwestern University MATERIALS AND METHODS FOR ACTIVATING ANTIGEN-SPECIFIC T CELL RESPONSES
EP4423140A4 (en) 2021-10-27 2025-10-01 Samyang Biopharm Usa Inc ANTI-MIC ANTIBODIES WITH VARIANT FC DOMAINS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120315287A1 (en) 2011-05-31 2012-12-13 University Of Washington Through Its Center For Commercialization Mic-binding antibodies and methods of use thereof
US20160368991A1 (en) * 2013-07-05 2016-12-22 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
WO2020086776A1 (en) * 2018-10-23 2020-04-30 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof

Also Published As

Publication number Publication date
KR20230012072A (ko) 2023-01-25
EP4178678A1 (en) 2023-05-17
US12139539B2 (en) 2024-11-12
JP2026021336A (ja) 2026-02-10
US20230235065A1 (en) 2023-07-27
TWI925854B (zh) 2026-05-21
WO2022010847A1 (en) 2022-01-13
US20250026837A1 (en) 2025-01-23
TW202216776A (zh) 2022-05-01
AU2021305084A1 (en) 2023-02-02
CA3184940A1 (en) 2022-01-13
JP2023532852A (ja) 2023-08-01
KR20230152783A (ko) 2023-11-03
JP7854948B2 (ja) 2026-05-07
CN116249716A (zh) 2023-06-09

Similar Documents

Publication Publication Date Title
JP7797614B2 (ja) Ｃｄ１２３結合性ポリペプチド及びその使用
JP7824999B2 (ja) ＣＬＥＣ１２ａ結合性ポリペプチド及びその使用
KR102690145B1 (ko) 항ctla-4 항체의 사용
JP7525510B2 (ja) Ｃｄ３３結合性ポリペプチド及びその使用
US20250026837A1 (en) MIC Antibodies and Binding Agents and Methods of Using the Same
WO2023010483A1 (en) Anti-human cxcr5 antibody and uses thereof
CA3092434A1 (en) Compositions of a novel anti-human ceacam6 antibody and uses thereof
JP2025538606A (ja) 抗ｃｃｒ８抗体及びその使用
US20250230246A1 (en) Anti-mic antibodies with variant fc domains
CN107148474A (zh) 抗人Gas6单克隆抗体
CN117279954A (zh) 抗人cxcr5抗体及其用途
HK40087490A (en) Mic antibodies and binding agents and methods of using the same
EA046221B1 (ru) Cd33-связывающие полипептиды и их применение
HK40104546A (en) Anti-human cxcr5 antibody and uses thereof
EA046257B1 (ru) Clec12a-связывающие полипептиды и их применение

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601